Menu
Logo

Percentage of patients who demonstrated a treatment response, defined by ≥%20 and ≥%50 decreases in PANSS total score respectively at month 6

header-Trevicta
Percentage_of_patients

Adapted from Hargarter L et al. 2016.
*Fisher’s exact test
ITT, intention to treat; PANSS, Positive and Negative Syndrome Scale.

The aim of this post hoc analysis from a single-arm, multicentre, open-label, 6-month
interventional study in non-acute but symptomatic patients with schizophrenia previously
unsuccessfully treated with oral antipsychotics was to explore treatment response, functional
outcomes, safety and tolerability of flexible doses of once-monthly paliperidone palmitate in
recently diagnosed (≤3 years) and chronic (>3 years) adult non-acute but symptomatic patients
with schizophrenia.5


The ITT population consisted of 593 patients and included 233 (39.3%) recently diagnosed and
360 (60.7%) chronic patients. The primary efficacy outcome for stable but symptomatic patients
switched due to unsuccessful treatment with the previous oral AP was the percentage of
patients achieving treatment response, defined as ≥20% improvement in PANSS total score
from baseline (Day 1) to last-observation-carried-forward (LOCF) endpoint (at 6 months or early
discontinuation).5

PP1M was initiated at 150 mg eq on Day 1 and 100 mg eq on Day 8 (±2 days) intramuscularly.
At initiation of PP1M, patients were tapered off their previous oral AP, preferably within a
maximum of 4 weeks. Thereafter, PP1M was administered once monthly (±7 days), using flexible
maintenance dosages, preferably within the range of 50 to150 mg eq, based upon the clinical
judgement of the treating physician.5

AP, antipsychotic

References
1. INVEGA® Ministry of Health approved leaflet, 18/3/2019.
2. Risperdal® Ministry of Health approved leaflet, 16/12/2019.
3. INVEGA SUSTENNA® Ministry of Health approved leaflet, 18/3/2019.
4. TREVICTA® Ministry of Health approved leaflet.19/5/2019.
5. Hargarter L, Bergmans P, Cherubin P, et al. Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia. Expert Opin Pharmacother. 2016;17(8):1043-53.

footer-Trevicta

CP-242852